Back to Archived News
Cytori Expands Patent Protection for the Celution System and Uses for Adipose Derived Stem and Regenerative Cells
Monday, July 13, 2009
San Diego, CA -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) recently received a Notice of Allowance from the U.S. Patent and Trademark Office related to uses of the Celution® System for the treatment of bone related disorders. Specifically, the allowed claims cover prosthetic devices that can be seeded with adipose derived stem and regenerative cells for use in bone healing and regeneration.
In addition, the Company received a second Notice of Allowance related to methods of obtaining clinically safe outputs from the Celution® System. The allowed claims cover methods of testing the Celution® output for contaminants such as red blood cells, lipids, enzymes, aggregates, and endotoxins, among other things.
Cytori’s intellectual property portfolio currently includes 14 issued U.S. and international patents including U.S. Patent No. 7,514,075 (the ‘075 patent), which was recently issued on April 7, 2009. With more than 40 issued claims, the ‘075 patent expands protection for the Celution® System. Key patent claims cover multiple reagents and additives that are critical for optimizing intravascular delivery of the Celution® System output for indications such as cardiovascular disease, liver disease and renal failure.
About Cytori
Cytori develops and globally commercializes regenerative medicine technologies, which provide real-time, point-of-care access to clinical grade regenerative cells. Our technology is incorporated into two product families. The Celution®-related products are sold throughout Europe and Asia primarily into the cosmetic and reconstructive surgery market and are under evaluation by the U.S. FDA. Our StemSource® products are sold globally for cell banking and research applications. We are also developing additional clinical uses of our technology for the treatment of multiple medical conditions, including cardiovascular disease, urinary tract disorders, and wound related conditions. To commercialize our technology, Cytori has partnered with global and regional leaders in healthcare such as Olympus Corporation, GE Healthcare, and Green Hospital Supply. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.
Back to Archived News
